The effect of the proprietary adjuvant MF59 on the immunogenicity of a recombinant hepatitis B virus (HBV) vaccine, PreS2+SAg, was investigated in baboons. The magnitude and duration of the antibody response to hepatitis B surface antigen (anti-HBs) induced by the HBV/MF59 vaccine was compared with the same antigen combined with alum and with two licensed alum vaccines. After one immunization, the HBV/MF59 vaccine generated anti-HBs titers> 10 mIU/mL in a greater proportion of animals, and mean titers were 26-to 84-fold higher than titers from alum vaccines. After a third immunization, the HBV/MF59 vaccine generated titers 38-to 127-fold higher than alum vaccines. Seven months after the third immunization, HBV/MF59 elicited titers 75-to 472-fold higher than alum vaccines. The dramatic immune response elicited by HBVIMF59 in baboons suggests that MF59 may be a desirable adjuvant for use in improved HBV vaccines for humans.
MF59 Adjuvant Enhances the Antibody Response to Recombinant Hepatitis B Surface Antigen Vaccine in Primates
The effect of the proprietary adjuvant MF59 on the immunogenicity of a recombinant hepatitis B virus (HBV) vaccine, PreS2+SAg, was investigated in baboons. The magnitude and duration of the antibody response to hepatitis B surface antigen (anti-HBs) induced by the HBV/MF59 vaccine was compared with the same antigen combined with alum and with two licensed alum vaccines. After one immunization, the HBV/MF59 vaccine generated anti-HBs titers> 10 mIU/mL in a greater proportion of animals, and mean titers were 26-to 84-fold higher than titers from alum vaccines. After a third immunization, the HBV/MF59 vaccine generated titers 38-to 127-fold higher than alum vaccines. Seven months after the third immunization, HBV/MF59 elicited titers 75-to 472-fold higher than alum vaccines. The dramatic immune response elicited by HBVIMF59 in baboons suggests that MF59 may be a desirable adjuvant for use in improved HBV vaccines for humans.
Commercially available hepatitis B virus (HBY) vaccines are safe and effective in eliciting a protective immune response in 90%-95% of young healthy subjects [1, 2] . However, three immunizations are usually required to achieve this level of protection [3 -7] . The persistence of antibodies to hepatitis B surface antigen (anti-HBs), which decline rapidly by 6 months after the third immunization [1, [8] [9] [10] , depends on the peak antibody level achieved after three doses of vaccine [11] [12] [13] [14] [15] . Among people who respond to vaccination, the risk of acquiring HBV infection increases as anti-HBs levels become undetectable, although the risk of developing clinical disease remains very low [12, 14, [16] [17] [18] . Furthermore, the immunization regimen (injections at 0, 1, and 6 months) does not facilitate compliance in the general population.
Essential elements for the development of an improved HBY vaccine include induction of protective levels of anti-HBs antibodies with fewer immunizations and strong antibody responses to ensure longevity of protection. Other desirable features include generation of protective anti-HBs antibodies in persons who usually respond poorly. The latter include immunosuppressed individuals infected with human immunodefi-ciency virus (HIV) [17, 19] ; renal transplant patients, who have poor [9%-36%] seroconversion rates after vaccination; persons undergoing hemodialysis, who have an increased risk of acquiring HBV infection [20] [21] [22] [23] [24] ; and persons >40 years old, who have fewer anti-RBs responses and decreased antiHBs titers with each decade of life [25] [26] [27] .
Several approaches have been used to develop improved HBV vaccines, including the addition of larger HBY envelope proteins (PreS 1 and PreS2) to the original vaccine formulation, which consists of hepatitis B surface antigen (HBsAg) alone. Anti-PreS2 antibodies generated in natural infection appear earlier than anti-RBs antibodies and contribute to virus clearance [28] [29] [30] . Immunologic nonresponsiveness to HBsAg has been overcome by PreS I/PreS2-containing vaccines in some mouse strains [31, 32] . Also, chimps immunized with a synthetic PreS2 peptide were protected from challenge with live HBV [33] . The PreSI and PreS2 antigens may provide T cell epitopes that could generate T cell helper activity and promote an increased antibody response to HBsAg in genetic nomesponders [34] . The PreS2 region of the HBY envelope S antigen contains the principal epitope capable of inducing T cell proliferative activity in human peripheral blood mononuclear cells from vaccinees given the yeast-derived PreS2+SAg vaccine [35] . Other attempts to improve the immune response to HBY vaccine have included immunization at different anatomic injection sites [25, 36] , higher doses of HBsAg [4, 26, 27, 37] , more booster immunizations [15, [38] [39] [40] , increased time between boosts [41, 42] , and alteration of the form of surface antigen used [43] .
Improved adjuvants have also been considered as a means of improving HBY vaccine performance. Currently, all hepatitis B vaccines licensed for human use have been formulated with aluminum salts (alum), the only adjuvant approved by the Food and Drug Administration for use in humans. While alum has a good safety record, it is a relatively weak adjuvant and is inconsistent in its ability to stimulate cell-mediated immunity [44] . Also, while particulate HBsAg can elicit cytotoxic T cell responses, aluminum hydroxide-adsorbed HBsAg has not [44] . Adjuvants tested with HBV vaccine have included immune-stimulating complexes [45] , the Syntex adjuvant formulation [46] , interleukin-l peptide [47] , Algammulin (gamma inulin/alum hybrid adjuvant) [48] , biodegradable polyglycolic acid microspheres containing encapsulated-HBsAg [49] , liposomes [50] , Ribi adjuvant [51] , steryl tyrosine and amide analogues [52] , and muramyl dipeptides [53] . While most of these adjuvants had greater immune responses than alum, these studies were largely restricted to studies in guinea pigs and mice.
A potential adjuvant for use with HBV vaccine is the proprietary adjuvant MF59 (Chiron). MF59 is an oil-in-water emulsion consisting of the metabolizable oil squalene and the surfactants sorbitan monoleate (Tween 80) and sorbitan trioleate (Span 85; Sigma, St. Louis). MF59 has extended stability and small uniform oil droplet size «250 nm), properties important in potentiating immunostimulatory activity [54, 55] . MF59 has been combined with a number of subunit vaccines and administered to a variety of animal species, including nonhuman primates [54, 55] . MF59 has augmented the antigen-specific humoral and T cell responses to subunit vaccines significantly better than alum or incomplete Freund's adjuvant in all animal species tested [55] . In clinical trials, MF59 adjuvant has been used with herpes simplex virus (HSV), HIV, influenza, and cytomegalovirus (CMV) vaccines in >6000 human volunteers [56] [57] [58] [59] [60] and was highly immunogenic without significant local or systemic side effects.
The present study tested the immune response of a nonhuman primate (baboon) to an MF59-adjuvanted recombinant CHO-derived HBV vaccine containing Sand PreS2 antigens (Chiron). The anti-HBs and anti-PreS2 antibody response against this vaccine combined with MF59 (HBV/ MF59) or alum (HBV/alum) was compared with two licensed alum-adjuvanted vaccines: vaccine 1 (Recombivax HB; Merck, West Point, PA), a recombinant yeast-derived HBV vaccine containing HBsAg alone, and vaccine 2 (GenHevac B; Pasteur, Marnes-la-Coquette, France), a recombinant CHO cell-derived HBV vaccine containing HBsAg and PreS2 antigens.
Materials and Methods

Vaccines
Adjuvants. MF59, an oil-in-water emulsion consisting of 5% squalene, 0.5% sorbitan monoleate, and 0.5% sorbitan trioleate was prepared under high-pressure homogenization in a Microfluidizer (MII0Y; Microfluidics, Newton, MA) as previously described [54] . Aluminum hydroxide gel (alum) (Alhydrogel: 2% Ah03, 3% Al[OHh; Superfos, Vedbaek, Denmark) was used in water at 0.5 mg/dose.
Antigens. Four groups of 5 baboons were immunized with one of four vaccines: recombinant CHO cell-derived hepatitis B vaccine containing 10 j..Lg of HBsAg and~5% PreS2 antigen per dose combined with MF59 adjuvant (1: 1 ratio) at 0.5 mL/dose (HBV /MF59) or with aluminum hydroxide (Alhydrogel) at 0.5 mg/0.5 mL dose (HBV/alum); vaccine 1, containing HBsAg at 10 ILg/dose in combination with aluminum hydroxide at 0.5 mg/1 mL dose; or vaccine 2, containing 20 ILg HBsAg and 20% PreS2 antigen per dose [6] in combination with aluminum hydroxide at 0.5 mg/0.5 mL dose. All vaccines were injected intramuscularly in the thigh at 0, 1, and 6 months using the same lots of protein! adjuvant for each vaccine group. At the time of each immunization, HBV was mixed with MF59 adjuvant, and animals were immunized within 1 h of vaccine preparation.
Animals. Eight female and 12 male baboons (Papio cynocephalus anubis and Papio cynocephalus hamadryas; Southwest Foundation for Biological Research, San Antonio, TX) 2-5 years old and weighing 9-22 kg were housed segregated by gender. Blood was obtained from the baboons via percutaneous venipuncture at weeks 0,2,4, 6, 8, 10, 14, 18,24,26,28, 32, 36, and 55. Antibody assays were done on serum prepared from clotted blood samples. While the scope of this study was not toxicologic in nature, gross observation of animals after each immunization and throughout this study did not reveal any granulomas, abscesses, or other side effects. One animal in the HBV/alum vaccine group died 3 days before the third immunization of causes unrelated to HBV vaccination: The pathology report attributed death to peritonitis after surgery to remove massive hair balls obstructing the stomach and intestine.
Detection of Antibody to HBV Proteins
Antibody responses to HBsAg were measured by a commercial EIA (AUSAB; Abbott Laboratories, Abbott Park, IL) and by an in-house ELISA against several different forms of HBsAg (CHO cell-derived, native human plasma-purified, and recombinant yeast cell-derived). Antibody responses to PreS2 were measured by ELISA against a synthetic peptide spanning aa 1-55, representing full-length PreS2.
EIA. For the quantitative determination of antibodies to HBsAg in serum, solid-phase EIA test kits were used concurrently with AUSAB quantitation standards (Abbott Laboratories), according to the manufacturer's instructions. In brief, baboon serum specimens were serially diluted in specimen dilution buffer (negative human plasma). Serum specimen dilutions, negative and positive controls, and blanks were tested with a panel of five (human) serum standards with known anti-HBs concentrations (0, 15, 40, 75, and 150 mIU/mL) and incubated with HBsAg-coated beads (subtypes ad and ay, human plasma-derived). Specimens with absorbance values outside the standard curve were diluted further and retested. Using the specimen absorbance value, the corresponding concentration of anti-HBs expressed in milliintemational units per milliliter was determined from the standard curve. For diluted specimens, the lowest dilution of the specimen that resulted in a value of 0-150 mIU/mL, after multiplying by the dilution factor, was used to arrive at a final concentration. Anti-HBs antibody concentrations :;?: 10 mIU/mL are considered protective in humans [61, 62] . Since no protection level can be established in baboons, this antibody level is used only as a guideline in the present study.
ELISA. Baboon serum samples were analyzed by ELISA in 96-well round-bottom plates (Maxisorp; Nunc, Naperville, IL) coated with 100 ILL/well HBV antigen at 2 j..Lg/mL in Dulbecco' s PBS. All incubations were at 37°C for 1 h. Plates were coated with each of the following HBV antigens: recombinant CHO cellderived PreS2+SAg (HBV), recombinant yeast cell-derived HBsAg, and human plasma-purified HBsAg (BiosPacific, Emeryville, CA) and synthetic full-length (aa 1-55) PreS2 peptide (Research Genetics, Huntsville, Alabama). Between each incubation step, plates were washed with ELISA wash buffer (137 mM NaCl, 0.05% Triton X-IOO) and patted dry. Each serum sample was diluted 1:5 serially across eight wells in ELISA dilution buffer (1% Triton X-IOO, 0.1% casein, 100 mMNa2HP04, 0.5 M NaCl, and 0.01% thimerosal, pH 7.5). Goat anti-monkey IgG horseradishperoxidase-conjugated antibody (Cappel, West Chester, PA) was used at 1:5000 in dilution buffer. Plates were developed at room temperature with TMB (3,3'5,5'-tetramethylbenzidine) as suggested by the manufacturer (Kirkegaard & Perry, Gaithersburg, MD). The reaction was stopped with the addition of 2 N HCl acid, and absorbance values were determined at 450 nm. The titer was defined as the reciprocal of the serum dilution that gave an ELISA absorbance of 0.5. All samples were tested in duplicate wells on separate plates, and the titers were calculated as the geometric mean of the two values.
Statistics
Values for each group are reported as the geometric mean and SE for 5 animals. One animal in HBV/alum group died 3 days before the third immunization (at 24 weeks) of a condition not related to immunization with HBV vaccine. Therefore, group mean titers for subsequent time points were calculated based on the remaining 4 animals. Baboons with anti-HBs antibody concentrations < 1 mIU/mL by EIA were assigned a value of 1 to facilitate the determination of the geometric mean concentration for the group. Animals with ELISA titers of 1-5 were assigned a value of 5 in order to determine the group geometric mean. Statistical analysis was done by analysis of variance (StatView; Abacus Concepts, Berkeley, CA). Pairwise comparisons between HBV/MF59 and the alum vaccines were made using Fisher's protected leastsquares difference test, and P~.05 was considered significant.
Results
Anti-Hils antibody levels are enhanced by MF59. The concentration of anti-HBs antibody generated in baboons immunized at 0, 1, and 6 months with MF59 and alum-adjuvanted HBV vaccines, as measured by EIA, is shown in table 1. All preimmunization serum samples tested negative (EIA) for antiHBs reactivity (data not shown). Two weeks after a single immunization with HBVIMF59 vaccine, all 5 baboons had antiHBs antibody concentrations > 10 mIU/mL. In comparison, 4 of 5 baboons that received HBV/alum vaccine had antibody concentrations > 10 mIU/mL. The commercial alum-adjuvanted vaccines I and 2 elicited anti-HBs antibody levels> 10 mIU/mL in 2 of 5 and 3 of 5 baboons, respectively. After the primary vaccination, the MF59-adjuvanted vaccine induced geometric mean anti-HBs antibody levels that were 26-, 63-, and 84-fold higher than those induced by HBV/alum, vaccine I, and vaccine 2, respectively. The differences in antibody responses between HBV/MF59 and vaccine I approached statistical significance (P = .058) and were significant between HBVIMF59 and vaccine 2 (P = .048).
After the second immunization (table 1), all animals but 1 (vaccine I group) had antibody levels> 10 mIU/mL. However, the geometric mean antibody concentration for HBV IMF59 vaccine recipients was 26-fold higher than for HBV/alum, 123-fold higher than for vaccine 1, and 106-fold higher than for vaccine 2 recipients. These differences were highly significant (P~.008).
The HBV/MF59 adjuvant vaccine induced high antibody levels that remained nearly unchanged for 5 months after the second immunization (table 1; figure 1 ). At the time of the third vaccination (24 weeks) geometric mean antibody concentrations for HBV/MF59-immunized animals were 16-fold higher than for HBV/alum, 53-fold higher than for vaccine 1, and 15-fold higher than for vaccine 2 recipients, and these differences remained highly significant (P~.005).
The third injection of all HBV vaccines generated a strong boost in antibody responses. After this injection, HBV/MF59 vaccine-boosted anti-HBs antibody concentrations were 42-fold higher than for HBV/alum, 127-fold higher than for vaccine 1, and 38-fold higher than for vaccine 2 recipients (P. 003). The increase in antibody response provided by MF59 versus alum in baboons immunized with HBV vaccine was higher than previously measured in baboons immunized with HSV gD2 and HIV gp120 vaccines adjuvanted with MF59 or with alum. In baboons immunized with gD2/MF59, anti-gD2 titers were 5-fold higher than in those given gD2/alum vaccine; in baboons immunized with gp120/MF59, anti-gpl20 titers were 26-fold higher than titers for baboons immunized with gpl20/alum [54] .
The longevity of the anti-HBs response is shown in figure  I . After each immunization, an antibody boost was observed in each vaccine group: The most pronounced rise in antibody concentration was in HBVIMF59 vaccine recipients. Peak antibody titers occurred 2 weeks after the third vaccination for all groups. One month after the third immunization, the MF59-adjuvanted vaccine group maintained anti-HBs antibodies that were 86% of the peak concentration compared with the alumadjuvanted vaccines, which were at 50%-61 % of their peak response levels. Two months after the third immunization, the HBV/MF59 vaccine group was at 36% of its peak antibody response, and alum-adjuvanted vaccines were at 22%-26% of peak antibody response levels. Three months after the third vaccination, animals given MF59-adjuvanted HBV vaccine were at 25% of their maximum anti-HBs response compared with the alum-adjuvanted HBV-vaccinated baboons, which were at 4%-17% of their peak responses. Seven months after the third immunization, the HBV/MF59 group mean titer was 11% of its peak anti -HBs antibody concentration level, and the alum-adjuvanted HBV vaccine groups were 2%-6% of their peak responses. The longevity of the antibody response elicited by the HBV/MF59 vaccine was demonstrated by a sustained NOTE. Data arc geometric mean titers (GMTs) of sera. Antibody concentrations (mTU/mL) were determined by AUSAB ETA (Abbott). * Vaccines were given at weeks 0, 4, and 24. HBV/MF59 and HBV/alum (Chiron); vaccine 1, Recombivax HB (Merck); vaccine 2, GenHevac B (Pasteur).
t Pairwise comparisons to MF59 vaccine group by analysis of variance (StatView; Abacus Concepts).
anti-HBs antibody concentration 75-to 472-fold higher than the other three HBV vaccines with alum, even 7 months after the last immunization. To eliminate any potential bias presented by human-derived HBsAg capture antigen in the EIA, serum samples were also quantified by ELISA using CHO cell-derived HBsAg (CB HBV) and native human plasma-derived and recombinant yeast cell-derived HBsAg (both BiosPacific). A CHO cellderived HBsAg was used as the ELISA capture antigen, because the HBV -and the vaccine 2 -vaccinated animals received CHO cell-derived PreS2+SAg as the immunizing antigen. A recombinant yeast-derived HBsAg (BiosPacific) was used as the ELISA capture antigen, because vaccine I animals received yeast cell-derived HBsAg immunizing antigen. As an additional control, a human plasma-derived RBsAg (BiosPacific) was also used as an ELISA capture antigen, because it is representative of HBsAg in natural infection.
Results show that the increase in antibody response provided by MF59 compared with alum was similar for the four assays (EIA and ELISAs with CRO cell-derived, human plasmaderived, and yeast-derived antigens). The anti-RBs (CHO cellderived capture antigen) mean antibody titer for the RBVI MF59 group was 38-to 198-fold higher than the titers for the alum-adjuvanted RBV vaccines. The mean anti-RBs (native human plasma-derived capture antigen) antibody titer was 40-to 106-fold higher for the HBV/MF59 vaccine compared with alum vaccine titers. The anti-RBs (yeast cell-derived capture antigen) mean antibody titer was 8-to 13-fold higher for the RBV/MF59 vaccine than for alum vaccines. While the increase provided by MF59 was somewhat lower using the yeast cell- derived antigen in the ELISA compared with the mammalianproduced antigens, this difference remained statistically significant. Reactivity against the human plasma-derived antigen would be expected to be the most relevant measure of protective immunity, as this antigen form most closely resembles the reactive virus (data not shown).
Anti-PreS2 antibody levels enhanced by MF59. AntiPreS2-specific antibody responses are shown in table 2. Two weeks after the first immunization, the antibodies were found in all 5 baboons in the HBV/MF59 vaccine group. In contrast, only 2 animals in the HBVlalum vaccine and 2 in the vaccine 2 group had anti-PreS2 titers >5. As expected, baboons given vaccine 1 did not generate antibodies to PreS2 at any time. Two weeks after the second immunization, the HBVIMF59-vaccinated baboons had increased anti-PreS2 titers (19-to 41- fold higher than the two alum-adjuvanted PreS2 +SAg vaccines). At the time of the third immunization (week 24), anti-PreS2 antibody titers were still measurable in all 5 HBVI MF59-vaccinated baboons but only in I animal in the HBVI alum vaccine group. No baboons in the vaccine 2 group had measurable anti-PreS2 antibodies at the time of the third immunization. Two weeks after the third vaccination, the HBV/MF59 and the vaccine 2 groups had equivalent anti-PreS2 antibody titers. Seven months after the third immunization, however, measurable anti-PreS2 titers were still detected in all 5 baboons in the HBV/MF59 group but only in 1 in the vaccine 2 group.
Discussion
In this study, the MF59 adjuvant significantly increased antibody responses to HBV vaccine in baboons. A major improvement to current HBV vaccines would be enhanced immunogerucrty, so that protective antibody levels are generated with fewer immunizations. Using a nonhuman primate model, the MF59 adjuvant played a key role in generating an earlier antiHBs antibody response than seen with alum adjuvant. Another key to improving responses to HBV vaccines is to elicit high protective antibody levels that are of long duration. In baboons, MF59 adjuvant elicited a dramatic anti-HBs response and contributed to sustained antibody levels that were significantly higher than in alum vaccines.
The marked duration of high titer anti-HBs antibody generated by the MF59 adjuvant suggests that longer-lasting immunity could be achieved with this adjuvant than with alum. To estimate the duration ofanti-HBs response in humans ofMF59-adjuvanted HBV vaccine compared with the alum-adjuvanted vaccines, we used a mathematical model [63] based on the baboon data. Results indicated that titers> 10 mIU/mL evoked by MF59-adjuvanted HBV vaccine would exceed the span of a human life, and protection generated by the alum-adjuvanted commercial HBV vaccines would be 4-8 years.
To estimate the relevance of the baboon model, we compared human responses to commercial HBV vaccines with those in the present baboon study. Human antibody responses to alumadjuvanted HBsAg vaccines (after three immunizations) are 962-5846 mIU/mL (mean, 2400) [2, 3, 5, 11, 42] . Human antibody responses to PreS2 +SAg vaccines adjuvanted with alum are 688-3358 mIU/mL (mean, 1660) [5, 25, 41, 64] . In our study with baboons, antibody responses to alum-adjuvanted HBV vaccines after three immunizations were 6340-17537 mIU/mL. The baboon response to the HBsAg vaccine with alum (vaccine 1) was about three times higher than reported human values. The baboon response to PreS2 +SAg vaccines with alum was~10 times higher than reported human re- sponses. Thus, the baboon response to HBV vaccines appears to be elevated (~3-to l O-fold) from human responses. In previous studies, the baboon model has been a good predictor of human responses to HIV and HS V vaccines tested in combination with MF59 adjuvant. While baboons show a stronger immune response than humans to HBV vaccines, the baboon data suggest that the human response to HBV vaccine in combination with MF59 could be much higher than the response to alum-adjuvanted HBV vaccines at all time points. Therefore, the MF59 adjuvant has the potential to improve responses to HBV vaccine by eliciting protective antibody responses with fewer immunizations and of maintaining protective high-titer antibody for a lifetime. It might also enhance responses in low-responder groups.
The excellent safety record of MF59 adjuvant with HSV, HIV, influenza, and CMV vaccines in humans [56] [57] [58] [59] and the dramatic immunogenicity provided by MF59 with HBV vaccine in the primate model make it a good candidate for an improved HBV vaccine.
